Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

dorsaVi Ltd's ViMove approved for sale in New Zealand


Monday, 7 Jul 2014 07:11pm EDT 

dorsaVi Ltd:Says regulatory approval for use and sale of ViMove from Medsafe, New Zealand Medicines and Medical Devices Safety Authority.ViMove is dorsaVi‚Äôs product for healthcare professional use and is currently available at medical, physiotherapy and osteopathy clinics in Australia, Canada and Europe.